TRAUMADORNASE试验方案:雾化阿法链道酶减少通气创伤患者中重度低氧血症
TRAUMADORNASE是一项前瞻性、随机、多中心、双盲、安慰剂对照试验,针对通气严重创伤患者,评估雾化阿法链道酶能否将7天内中重度低氧血症发生率从45%降至30%。每臂随机250例,采用贝叶斯方法分析,已于2019年3月启动招募。
要点
- 雾化阿法链道酶可能通过裂解NETs和DAMPs的DNA骨架减轻创伤性肺损伤。
- 主要目标是将7天内中重度低氧血症发生率从45%降至30%。
- 每臂250例,双盲安慰剂对照,采用全贝叶斯统计方法。
核心结论
- 若早期雾化阿法链道酶能降低严重创伤患者中重度低氧血症发生率,该策略或易在创伤救治中推广。
研究设计与样本
- 机构主导、多中心、双盲、安慰剂对照随机试验,纳入通气创伤患者,每治疗臂随机250例。
主要发现
- 原文为试验方案,未报告试验结果。
关键数值与推荐
- 主要目标:7天内中重度低氧血症发生率从45%降至30%。
- 次要目标:改善肺功能、降低发病率与死亡率。
- 随机化通过安全网络系统进行,统计分析含描述性与推断性贝叶斯步骤。
临床怎么用
- 原文未报告临床实践推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Acute respiratory distress syndrome continues to drive significant morbidity and mortality after severe trauma. The incidence of trauma-induced, moderate-to-severe hypoxaemia, according to the Berlin definition, could be as high as 45%. Its pathophysiology includes the release of damage-associated molecular patterns (DAMPs), which propagate tissue injuries by triggering neutrophil extracellular traps (NETs). NETs include a DNA backbone coated with cytoplasmic proteins, which drive pulmonary cytotoxic effects. The structure of NETs and many DAMPs includes double-stranded DNA, which prevents their neutralization by plasma. Dornase alfa is a US Food and Drug Administration-approved recombinant DNase, which cleaves extracellular DNA and may therefore break up the backbone of NETs and DAMPs. Aerosolized dornase alfa was shown to reduce trauma-induced lung injury in experimental models and to improve arterial oxygenation in ventilated patients. METHODS: TRAUMADORNASE will be an institution-led, multicentre, double-blinded, placebo-controlled randomized trial in ventilated trauma patients. The primary trial objective is to demonstrate a reduction in the incidence of moderate-to-severe hypoxaemia in severe trauma patients during the first 7 days from 45% to 30% by providing aerosolized dornase alfa as compared to placebo. The secondary objectives are to demonstrate an improvement in lung function and a reduction in morbidity and mortality. Randomization of 250 patients per treatment arm will be carried out through a secure, web-based system. Statistical analyses will include a descriptive step and an inferential step using fully Bayesian techniques. The study was approved by both the Agence Nationale de la Sécurité du Médicament et des Produits de Santé (ANSM, on 5 October 2018) and a National Institutional Review Board (CPP, on 6 November 2018). Participant recruitment began in March 2019. Results will be published in international peer-reviewed medical journals. DISCUSSION: If early administration of inhaled dornase alfa actually reduces the incidence of moderate-to-severe hypoxaemia in patients with severe trauma, this new therapeutic strategy may be easily implemented in many clinical trauma care settings. This treatment may facilitate ventilator weaning, reduce the burden of trauma-induced lung inflammation and facilitate recovery and rehabilitation in severe trauma patients. TRIAL REGISTRATION: ClinicalTrials.gov, NCT03368092. Registered on 11 December 2017.
引用
- Pottecher J, Noll E, Borel M, et al. Protocol for TRAUMADORNASE: a prospective, randomized, multicentre, double-blinded, placebo-controlled clinical trial of aerosolized dornase alfa to reduce the incidence of moderate-to-severe hypoxaemia in ventilated trauma patients. Trials. 2020. PMID: 32183886. doi:10.1186/s13063-020-4141-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。